Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels Cohort

Should We Use bDMARDs as an Induction Therapy in Early and Severe Rheumatoid Arthritis? Results at 5 years from the ERA UCLouvain Brussels Cohort

Abstract Introduction This study sought to analyze the benefit of an early induction therapy with a biological disease-modifying anti-rheumatic drugs (bDMARD) during the first year of treatment with a 5-year follow-up in early rheumatoid arthritis (ERA). Methods We included ERA patients from the UCL...

Full description

Bibliographic Details
Main Authors: Emilie Sapart, Tatiana Sokolova, Stéphanie de Montjoye, Stéphanie Dierckx, Adrien Nzeusseu, Aleksandra Avramovska, Laurent Meric de Bellefon, Patrick Durez
Format: Article
Language:English
Published: Adis, Springer Healthcare 2023-05-01
Series:Rheumatology and Therapy
Subjects:
Rheumatoid arthritis
Early arthritis
Biological versus conventional synthetic DMARDs
Online Access:https://doi.org/10.1007/s40744-023-00551-3

Similar Items

Similar Items